OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
Labcorp (NYSE: LH) has completed the acquisition of select assets from BioReference Health, a subsidiary of OPKO Health (Nasdaq: OPK), for $237.5 million. The deal includes BioReference Health's laboratory testing businesses in clinical diagnostics and reproductive and women's health outside of New York and New Jersey, generating approximately $100 million in annual revenue. This acquisition aims to enhance Labcorp's laboratory services network and expand access to its clinical services.
The transaction is expected to provide patients, physicians, and customers with greater access to Labcorp's comprehensive laboratory services and expanded testing capabilities. OPKO Health views this sale as a strategic move to improve efficiencies and enhance productivity of BioReference Health's operations, focusing on their core clinical diagnostics in New York and New Jersey and higher value testing segments.
OPKO Health (NASDAQ: OPK) reported Q2 2024 financial results and business highlights. Key points include:
1. Enrollment underway in MDX2001 Phase 1 trial for solid tumor cancers.
2. Global commercial launch of NGENLA® ongoing with Pfizer.
3. Entered $250 million note purchase agreement secured by NGENLA profit share payments.
4. Authorized $100 million share repurchase program.
5. Sale of select BioReference Health assets expected to close in Q3 for $237.5 million.
Financial results:
- Q2 2024 revenue: $182.2 million (vs $265.4 million in Q2 2023)
- Q2 2024 net loss: $10.3 million or $0.01 per share (vs $19.6 million or $0.03 per share in Q2 2023)
- Cash and cash equivalents: $40.6 million as of June 30, 2024
OPKO Health (NASDAQ: OPK) has announced it will release its second quarter 2024 financial results on August 7, 2024, after the U.S. financial markets close. The company will host a conference call and live audio webcast at 4:30 p.m. Eastern time on the same day to discuss the results and provide a business update. Senior management will also offer financial guidance during the call.
Participants are encouraged to pre-register for the conference call using a provided link. Those unable to pre-register can dial in using specific numbers for U.S. and International callers. A webcast of the call will be accessible through OPKO's Investor Relations page. Both telephone and webcast replays will be available for a time after the call.
OPKO Health (NASDAQ: OPK) has announced a $100 million share repurchase program, authorized by its Board of Directors. The program allows OPKO to repurchase shares through various methods, including open market purchases and block trades. With approximately 697 million shares outstanding as of June 30, 2024, this authorization represents about 10.1% of shares outstanding at the current stock price.
CEO Phillip Frost stated that the company believes its shares are significantly undervalued and offer an attractive investment opportunity. The repurchase program is expected to be funded from existing cash, cash equivalents, and future cash flows. OPKO's recent non-dilutive capital transaction with HealthCare Royalty and prior convertible debt refinancing have provided financial flexibility for this initiative.
OPKO Health (NASDAQ: OPK) has secured a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx), backed by profit share payments from Pfizer for NGENLA™, a pediatric growth hormone deficiency treatment. The deal allows OPKO to retain a significant portion of NGENLA's profit share payments in the near term while maintaining long-term upside and the full benefit of $100 million in potential milestone payments from Pfizer.
The note bears interest at the 3-month SOFR (minimum 4.0% per annum) plus 7.5% per annum, with a maturity date of July 2044 and interest-only payments for the first four years. This non-dilutive capital provides OPKO with financial flexibility to advance R&D activities, including multispecific antibody programs, and potentially repurchase shares and convertible notes.
OPKO Health (Nasdaq: OPK) will participate in the Jefferies Global Healthcare Conference from June 4-6, 2024, in New York City. The management team will engage in one-on-one meetings with investors and join a fireside discussion on June 6th at 10:30 a.m. Eastern time. The discussion will be webcast live and available for replay on the company’s investor relations webpage.
OPKO Health, Inc. (NASDAQ: OPK) reported first quarter 2024 business highlights and financial results. Highlights include an agreement with Labcorp to sell select assets of BioReference Health for $237.5 million, as well as FDA clearance for MDX2001, a tetraspecific antibody for solid tumor cancers. The global launch of NGENLA® by Pfizer is ongoing, with OPKO entitled to profit sharing and potential milestone payments. Financially, revenue declined to $173.7 million from $237.6 million in 2023, resulting in an operating loss of $71.5 million for Q1 2024.
OPKO Health, Inc. (NASDAQ: OPK) will release its financial results for the first quarter of 2024 on May 7, 2024. The company's senior management will discuss the results and provide financial guidance during a conference call and webcast.
Summary not available.
Summary not available.